At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADXN Addex Therapeutics Ltd
Closed 10-07 16:00:00 EDT
3.13
-0.05
-1.57%
盘后3.13
+0.000.00%
16:04 EDT
High3.16Low2.98Vol9.40K
Open3.15D1 Closing3.18Amplitude5.75%
Mkt Cap5.49MTradable Cap4.90MTotal Shares1.75M
T/O29.55KT/O Rate0.60%Tradable Shares1.57M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Press Release: Addex Therapeutics Announces Executive Management Changes
Dow Jones  ·  10-02
Press Release: Addex Therapeutics Announces Executive Management Changes
NASDAQ Trade Halt Volatility Trading Pause at 11:24 Am
Reuters  ·  09-28
NASDAQ Trade Halt Volatility Trading Pause at 11:24 Am
Press Release: Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
Dow Jones  ·  09-28
Press Release: Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
Press Release: Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
Dow Jones  ·  09-24
Press Release: Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
Press Release: ADDEX Raises USD 2.8 Million Through Its ATM Agreement and Extends Cash Runway to the Fourth Quarter 2027
Dow Jones  ·  08-26
Press Release: ADDEX Raises USD 2.8 Million Through Its ATM Agreement and Extends Cash Runway to the Fourth Quarter 2027
NASDAQ Trade Halt Volatility Trading Pause at 02:50 Pm
Reuters  ·  08-21
NASDAQ Trade Halt Volatility Trading Pause at 02:50 Pm
Addex Therapeutics announces publication of new ADX71743 preclinical research
TIPRANKS  ·  07-08
Addex Therapeutics announces publication of new ADX71743 preclinical research
Press Release: Addex Announces Publication of Research Highlighting Therapeutic Potential of Mglu7 Modulation in Regulating Sleep and Wakefulness
Dow Jones  ·  07-08
Press Release: Addex Announces Publication of Research Highlighting Therapeutic Potential of Mglu7 Modulation in Regulating Sleep and Wakefulness
Press Release: Addex Shareholders Approve All Resolutions at Annual General Meeting
Dow Jones  ·  06-30
Press Release: Addex Shareholders Approve All Resolutions at Annual General Meeting
Addex Therapeutics Reports Q1 2026 Net Loss Of CHF 1.71M Versus CHF 1.47M A Year Ago, Cash CHF 0.9M
Benzinga Earnings  ·  06-25
Addex Therapeutics Reports Q1 2026 Net Loss Of CHF 1.71M Versus CHF 1.47M A Year Ago, Cash CHF 0.9M
Press Release: Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones  ·  06-25
Press Release: Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Press Release: Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
Dow Jones  ·  06-22
Press Release: Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
Press Release: Addex Convenes Annual General Meeting 2026
Dow Jones  ·  06-05
Press Release: Addex Convenes Annual General Meeting 2026
Addex Closes 2025 With CHF 6.7M Net Loss And CHF 1.6M Cash, Regains ADX71149 Rights And Invests In Stalicla
Benzinga Earnings  ·  04-30
Addex Closes 2025 With CHF 6.7M Net Loss And CHF 1.6M Cash, Regains ADX71149 Rights And Invests In Stalicla
Press Release: Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
Dow Jones  ·  04-30
Press Release: Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
Addex Therapeutics announces GABAB PAM candidate data
TIPRANKS  ·  04-29
Addex Therapeutics announces GABAB PAM candidate data
Press Release: Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
Dow Jones  ·  04-29
Press Release: Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
Addex Therapeutics says spin-out company to complete NTX-253 study in Q2
TIPRANKS  ·  04-23
Addex Therapeutics says spin-out company to complete NTX-253 study in Q2
Press Release: Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
Dow Jones  ·  04-23
Press Release: Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
Press Release: Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
Dow Jones  ·  04-21
Press Release: Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Introduction

Company Name.
Addex Therapeutics Ltd
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Issue price:
--